Elizabeth Wulff-Burchfield, MD, discusses the role of immune checkpoint inhibitor combination therapy in metastatic renal cell carcinoma.
Elizabeth Wulff-Burchfield, MD, assistant professor, Divisions of Medical Oncology and Palliative Medicine and medical director of Palliative and Geriatric Oncology Services, The University of Kansas Health System, discusses the role of immune checkpoint inhibitor combination therapy in metastatic renal cell carcinoma (RCC).
The most common frontline treatments for patients with metastatic RCC include a number of checkpoint inhibitor combinations, either with other checkpoint inhibitors or tyrosine kinase inhibitors. Wulff-Burchfield says these regimens currently include axitinib (Inlyta) plus avelumab (Bavencio), axitinib plus pembrolizumab (Keytruda), and nivolumab (Opdivo) plus ipilimumab (Yervoy). Findings from the phase 3 CheckMate-9ER clinical trial demonstrated promise for the combination of nivolumab plus cabozantinib (Cabometyx) in this space as well.
There is worry in the community that preoperative checkpoint inhibition could increase risk of some dismal reactions, Wulff-Burchfield says, and this could make operation difficult. Given that this is not the same as neoadjuvant therapy and these patients need a response for quality of life, the ethical framework and data support use of these combination regimens with checkpoint inhibitors, but if operation is a secondary goal for the patient, she says she would consider this within the first 3 to 6 months.
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Deciding Factors for Front-Line Therapy in Metastatic RCC
April 17th 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on what factors influence physician decision making for frontline therapy in patients with metastatic renal cell carcinoma in the first article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Long-Term Ipi/Nivo RCC Data Show Durability Across Risk Groups
April 12th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the 8-year follow-up data of ipilimumab plus nivolumab in patients with advanced renal cell carcinoma In the first article of a 2-part series.
Read More